Novel hyaluronase variants with improved stability and pharmaceutical compositions containing same

A composition and variant technology, applied in the field of novel human PH20 variants or fragments thereof, can solve the problems of reducing the stability and deficiency of protein drugs

Pending Publication Date: 2021-12-24
ALTEOGEN
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

That is, co-administered recombinant PH20 can aggregate, reducing the stability of the protein drug
[0018] At t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel hyaluronase variants with improved stability and pharmaceutical compositions containing same
  • Novel hyaluronase variants with improved stability and pharmaceutical compositions containing same
  • Novel hyaluronase variants with improved stability and pharmaceutical compositions containing same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0127] Example 1: Construction of PH20 variants

[0128] To construct PH20 variants, the cDNA of wild-type PH20 (clone ID: hMU002604) was purchased from the Korean Human Gene Bank. Wild-type PH20 encodes amino acids from L36 to S490. The PH20 gene was amplified by polymerase chain reaction (hereinafter referred to as PCR) and inserted into the restriction enzyme sites XhoI and NotI of the pcDNA3.4-TOPO vector. For expression in ExpiCHO cells, the signal peptide of human growth hormone, human serum hormone or human Hyal1 was used as a signal peptide instead of the original signal peptide of PH20. For protein purification using HisTrap columns, the DNA sequence of the His-tag is located at the 3' end of the cDNA of PH20. Amino acid substitutions of the PH20 variants were made using PCR and confirmed by DNA sequencing.

[0129] The list of primers used to clone PH20 variants is summarized in Table 4 below, and the specific primer sequences are summarized in Table 5 below.

[...

Embodiment 2

[0236] Example 2: Properties of PH20 variants according to the invention

[0237] The structure and function of the protein were further investigated by studying variants comprising N-terminal and C-terminal cleavages based on the amino acid sequence of SEQ ID NO:3. The aggregation temperature shown in Table 7 is used as the analysis result of the performance and activity of the prepared variants.

[0238] The extent of expression and specific activity was analyzed by turbidity assay as described in Example 1. The results of the test are shown below. At this time, based on the limit of quantification (LOQ) set for each activity after purification in the culture medium, an activity exceeding 300 unit / mL in the culture medium is marked as ">LOQ", while an activity exceeding 15 unit after purification / μg is marked as ">LOQ". In the opposite case, the sign of the inequality changes. The performance level and quantification limit of the activity analysis and the test results b...

Embodiment 3

[0250] Example 3: Activity analysis of variants substituted with the sequences Hyal2, Hyal3 and Hyal4

[0251] The amino acid sequences of Hyal2 (TTSTETCQYLKDYLTRL), Hyal3 (SSSEEECWHLHDYLVDT) and Hyal4 (TASKANCTKVKQFVSSD) are the corresponding parts of hyaluronidases in the human body except Hyal1, replacing the amino acid sequence of M345 to I361 in the wild-type PH20 of SEQ ID NO:1 position to study how the stability of the protein changes.

[0252] The variants constructed by substituting the corresponding sequences Hyal2, Hyal3 and Hyal4 for the positions from M345 to I361 of mature wild-type PH20 (L36-S490) are referred to as "Hyal2-variant", "Hyal3-variant" and "Hyal3-variant", respectively. Hyal4-variant".

[0253] Hyal2-variant, Hyal3-variant and Hyal4-variant were constructed, then the thermostability of these variants was analyzed (see figure 2). As a result, the aggregation temperature of the Hyal2-variant measured by DLS was 48°C, which was 1.5°C higher than the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Cell densityaaaaaaaaaa
Login to view more

Abstract

The present application discloses novel PH20 variants or fragments thereof, human hyaluronidase having improved thermal stability and enzymatic activity, wherein the hyaluronidase is an enzyme that hydrolyzes hyaluronic acid, in particular to PH20 variants or fragments thereof comprising one or more amino acid residue substitutions in a variant having the amino acid sequence of SEQ ID NO: 3, and one or more amino acid residues are selectively deleted at the N-terminus and/or C-terminus.

Description

technical field [0001] The present invention relates to novel human PH20 variants or fragments thereof having increased enzymatic activity and thermostability compared to human hyaluronidase, an enzyme that hydrolyzes hyaluronic acid. In particular, the present invention relates to PH20 variants or fragments thereof comprising one or more substitutions, deletions and / or insertions of amino acid residues in a hyaluronidase variant having the amino acid sequence of SEQ ID NO:3 , and wherein one or more amino acid residues are selectively deleted from the N-terminus and / or C-terminus, a method for producing the PH20 variant or a fragment thereof, and a pharmaceutical combination comprising the PH20 variant or a fragment thereof thing. Background technique [0002] Human skin is composed of epidermis, dermis and subcutaneous fat layer, and there are six kinds of glycosaminoglycans in the skin. These glycosaminoglycans include hyaluronic acid, chondroitin sulfate, dermatan sulf...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N9/26A61K38/47A61K45/06A61P35/00
CPCC12N9/2408A61K45/06A61P35/00A61K38/00C12N9/2474C12N9/88C12Y302/01035C12Y402/02001C07K2319/02C07K2319/21A61K38/47C12N15/63C12N2320/30
Inventor 朴淳宰郑惠信李承柱金奎完宋炯楠
Owner ALTEOGEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap